You just read:

Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy

News provided by

Jazz Pharmaceuticals plc

24 Apr, 2017, 16:05 ET